Browsing by Author "Cordeiro, CR"

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
    Bousquet, J; Melén, E; Haahtela, T; Koppelman, GH; Togias, A; Valenta, R; Akdis, CA; Czarlewski, W; Rothenberg, M; Valiulis, A; Wickman, M; Akdis, M; Aguilar, D; Bedbrook, A; Bindslev-Jensen, C; Bosnic-Anticevich, S; Boulet, LP; Brightling, CE; Brussino, L; Burte, E; Bustamante, M; Canonica, GW; Cecchi, L; Celedon, JC; Loureiro, CC; Costa, E; Cruz, AA; Erhola, M; Gemicioglu, B; Fokkens, WJ; Garcia-Aymerich, J; Guerra, S; Heinrich, J; Ivancevich, JC; Keil, T; Klimek, L; Kuna, P; Kupczyk, M; Kvedariene, V; Larenas-Linnemann, DE; Lemonnier, N; Carlsen, KCL; Louis, R; Makela, M; Makris, M; Maurer, M; Momas, I; Morais-Almeida, M; Mullol, J; Naclerio, RN; Nadeau, K; Nadif, R; Niedoszytko, M; Okamoto, Y; Ollert, M; Papadopoulos, NG; Passalacqua, G; Patella, V; Pawankar, R; Pham-Thi, N; Pfaar, O; Regateiro, FS; Ring, J; Rouadi, PW; Samolinski, B; Sastre, J; Savouré, M; Scichilone, N; Shamji, MH; Sheikh, A; Siroux, V; Sousa-Pinto, B; Standl, M; Sunyer, J; Taborda-Barata, L; Toppila-Salmi, S; Torres, MJ; Tsiligianni, I; Valovirta, E; Vandenplas, O; Ventura, MT; Weiss, S; Yorgancioglu, A; Zhang, L; Latiff, AHA; Aberer, W; Agache, I; Al-Ahmad, M; Alobid, I; Ansotegui, IJ; Arshad, SH; Asayag, E; Barbara, C; Baharudin, A; Battur, L; Bennoor, KS; Berghea, EC; Bergmann, KC; Bernstein, D; Bewick, M; Blain, H; Bonini, M; Braido, F; Buhl, R; Bumbacea, RS; Bush, A; Calderon, M; Calvo-Gil, M; Camargos, P; Caraballo, L; Cardona, V; Carr, W; Carreiro-Martins, P; Casale, T; Sarabia, AMC; Chandrasekharan, R; Charpin, D; Chen, YZ; Cherrez-Ojeda, I; Chivato, T; Chkhartishvili, E; Christoff, G; Chu, DK; Cingi, C; de Sousa, JC; Corrigan, C; Custovic, A; D'Amato, G; Del Giacco, S; De Blay, F; Devillier, P; Didier, A; Teixeira, MD; Dokic, D; Douagui, H; Doulaptsi, M; Durham, S; Dykewicz, M; Eiwegger, T; El-Sayed, ZA; Emuzyte, R; Fiocchi, A; Fyhrquist, N; Gomez, RM; Gotua, M; Guzman, MA; Hagemann, J; Hamamah, S; Halken, S; Halpin, DMG; Hofmann, M; Hossny, E; Hrubisko, M; Irani, C; Ispayeva, Z; Jares, E; Jartti, T; Jassem, E; Julge, K; Just, J; Jutel, M; Kaidashev, I; Kalayci, O; Kalyoncu, AF; Kardas, P; Kirenga, B; Kraxner, H; Kull, I; Kulus, M; La Grutta, S; Lau, S; Thi, LL; Levin, M; Lipworth, B; Lourenço, O; Mahboub, B; Martinez-Infante, E; Matricardi, P; Miculinic, N; Migueres, N; Mihaltan, F; Mohammad, Y; Moniuszko, M; Montefort, S; Neffen, H; Nekam, K; Nunes, E; Tshipukane, DN; O'Hehir, R; Ogulur, I; Ohta, K; Okubo, K; Ouedraogo, S; Olze, H; Pali-Schöll, I; Palomares, O; Palosuo, K; Panaitescu, C; Panzner, P; Park, HS; Pitsios, C; Plavec, D; Popov, TA; Puggioni, F; Quirce, S; Recto, M; Repka-Ramirez, MS; Cordeiro, CR; Roche, N; Rodriguez-Gonzalez, M; Romantowski, J; Rosario, N; Rottem, M; Sagara, H; Serpa, FS; Sayah, Z; Scheire, S; Schmid-Grendelmeier, P; Sisul, JC; Sole, D; Soto-Martinez, M; Sova, M; Sperl, A; Spranger, O; Stelmach, R; Ulrik, CS; Thomas, M; To, T; Todo-Bom, A; Tomazic, PV; Urrutia-Pereira, M; Valentin-Rostan, M; Van Ganse, E; van Hage, M; Vasankari, T; Vichyanond, P; Viegi, G; Wallace, D; Wang, DY; Williams, S; Worm, M; Yiallouros, P; Yusuf, O; Zaitoun, F; Zernotti, M; Zidarn, M; Zuberbier, J; Fonseca, JA; Zuberbier, T; Anto, JM
    Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of one-airway-one-disease, coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the Epithelial Barrier Hypothesis. This review determined that the one-airway-one-disease concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme allergic (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll-Like Receptors and IL-17 for rhinitis alone as a local disease; IL-33 and IL-5 for allergic and non-allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono- or pauci-sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases.
  • No Thumbnail Available
    Item
    UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan
    Bousquet, J; Samolinski, B; Kaidashev, I; Maurer, M; Roche, N; Sousa-Pinto, B; Kurchenko, A; Stepanenko, R; Tsaryk, V; Klimek, L; Ventura, MT; Bedbrook, A; Czarlewski, W; Lysanets, Y; Kupczyk, M; Skolimowski, L; Kulus, M; Del Giacco, S; Ollert, M; Garcia-Aymerich, J; Cordeiro, CR; Yorgancioglu, A; Schlapbach, C; Amaral, R; Bonaglia, C; Bossé, I; Buquicchio, R; Christou, D; Fedoruk, G; Fontanesi, P; Gemicioglu, B; Giuliano, AFM; Lepore, P; Nakonechna, A; Neisinger, S; Pereira, AM; Ramanauskaite, A; Raciborski, F; Sitkauskiene, B; Sokhatska, O; Stepanenko, V; Stevanovic, K; Syzon, O; Kvedariene, V; de Vries, G; van Eerd, M; Valiulis, A; Fonseca, JA; Anto, JM; Haahtela, T; Schünemann, H; Zuberbier, T
    Eight million Ukrainians have taken refuge in the European Union. Many have asthma and/or allergic rhinitis and/or urticaria, and around 100,000 may have a severe disease. Cultural and language barriers are a major obstacle to appropriate management. Two widely available mHealth apps, MASK air (R) (Mobile Airways Sentinel NetworK) for the management of rhinitis and asthma and CRUSE (R) (Chronic Urticaria Self Evaluation) for patients with chronic spontaneous urticaria, were updated to include Ukrainian versions that make the documented information available to treating physicians in their own language. The Ukrainian patients fill in the questionnaires and daily symptom-medication scores for asthma, rhinitis (MASK air) or urticaria (CRUSE) in Ukrainian. Then, following the GDPR, patients grant their physician access to the app by scanning a QR code displayed on the physician's computer enabling the physician to read the app contents in his/her own language. This service is available freely. It takes less than a minute to show patient data to the physician in the physician's web browser. UCRAID- developed by ARIA (Allergic Rhinitis and its Impact on Asthma) and UCARE (Urticaria Centers of Reference and Excellence)- is under the auspices of the Ukraine Ministry of Health as well as European (European Academy of Allergy and Clinical immunology, EAACI, European Respiratory Society, ERS, European Society of Dermatologic Research, ESDR) and national societies.
  • No Thumbnail Available
    Item
    Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study
    Sousa-Pinto, B; Jácome, C; Pereira, AM; Regateiro, FS; Almeida, R; Czarlewski, W; Kulus, M; Shamji, MH; Boulet, LP; Bonini, M; Brussino, L; Canonica, GW; Cruz, AA; Gemicioglu, B; Haahtela, T; Kupczyk, M; Kvedariene, V; Larenas-Linnemann, D; Louis, R; Niedoszytko, M; Nhan, PT; Puggioni, F; Romantowski, J; Sastre, J; Scichilone, N; Taborda-Barata, L; Ventura, MT; Vieira, RJ; Agache, I; Bedbrook, A; Bergmann, KC; Amaral, R; Azevedo, LF; Bosnic-Anticevich, S; Brusselle, G; Buhl, R; Cecchi, L; Charpin, D; Loureiro, CC; de Blay, F; Del Giacco, S; Devillier, P; Jassem, E; Joos, G; Jutel, M; Klimek, L; Kuna, P; Laune, D; Pech, JL; Makela, M; Morais-Almeida, M; Nadif, R; Neffen, HE; Ohta, K; Papadopoulos, NG; Papi, A; Pétré, B; Pfaar, O; Yeverino, DR; Cordeiro, CR; Roche, N; Sá-Sousa, A; Samolinski, B; Sheikh, A; Ulrik, CS; Usmani, OS; Valiulis, A; Vandenplas, O; Vieira-Marques, P; Yorgancioglu, A; Zuberbier, T; Anto, JM; Fonseca, JA; Bousquet, J
    Background Validated questionnaires are used to assess asthma control over the past 1-4 weeks from reporting. However, they do not adequately capture asthma control in patients with fluctuating symptoms. Using the Mobile Airways Sentinel Network for airway diseases (MASK-air) app, we developed and validated an electronic daily asthma control score (e-DASTHMA). Methods We used MASK-air data (freely available to users in 27 countries) to develop and assess different daily control scores for asthma. Data-driven control scores were developed based on asthma symptoms reported by a visual analogue scale (VAS) and self-reported asthma medication use. We included the daily monitoring data from all MASK-air users aged 16-90 years (or older than 13 years to 90 years in countries with a lower age of digital consent) who had used the app in at least 3 different calendar months and had reported at least 1 day of asthma medication use. For each score, we assessed construct validity, test-retest reliability, responsiveness, and accuracy. We used VASs on dyspnoea and work disturbance, EQ-5D-VAS, Control of Allergic Rhinitis and Asthma Test (CARAT), CARAT asthma, and Work Productivity and Activity Impairment: Allergy Specific (WPAI:AS) questionnaires as comparators. We performed an internal validation using MASK-air data from Jan 1 to Oct 12, 2022, and an external validation using a cohort of patients with physician-diagnosed asthma (the INSPIRERS cohort) who had had their diagnosis and control (Global Initiative for Asthma [GINA] classification) of asthma ascertained by a physician. Findings We studied 135 635 days of MASK-air data from 1662 users from May 21, 2015, to Dec 31, 2021. The scores were strongly correlated with VAS dyspnoea (Spearman correlation coefficient range 0.68-0.82) and moderately correlated with work comparators and quality-of-life-related comparators (for WPAI:AS work, we observed Spearman correlation coefficients of 0.59-0.68). They also displayed high test-retest reliability (intraclass correlation coefficients range 0.79-0.95) and moderate-to-high responsiveness (correlation coefficient range 0.69-0.79; effect size measures range 0.57-0.99 in the comparison with VAS dyspnoea). The best-performing score displayed a strong correlation with the effect of asthma on work and school activities in the INSPIRERS cohort (Spearman correlation coefficients 0.70; 95% CI 0.61-0.78) and good accuracy for the identification of patients with uncontrolled or partly controlled asthma according to GINA (area under the receiver operating curve 0.73; 95% CI 0.68-0.78). Interpretation e-DASTHMA is a good tool for the daily assessment of asthma control. This tool can be used as an endpoint in clinical trials as well as in clinical practice to assess fluctuations in asthma control and guide treatment optimisation. Funding None. Copyright (c) 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.
  • No Thumbnail Available
    Item
    Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union's new recommendations on lung cancer screening
    Ward, B; Vasáková, MK; Cordeiro, CR; Yorgancioglu, A; Chorostowska-Wynimko, J; Blum, TG; Kauczor, HU; Samarzija, M; Henschke, C; Wheelock, C; Grigg, J; Andersen, ZJ; Koblízek, V; Májek, O; Odemyr, M; Powell, P; Seijo, LM
  • No Thumbnail Available
    Item
    AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation
    Bousquet, J; Barbara, C; Bateman, E; Bel, E; Bewick, M; Chavannes, NH; Cruz, AA; Haahtela, T; Hellings, PW; Khaltaev, N; Carlsen, KL; Muraro, A; Cordeiro, CR; Rosado-Pinto, J; Samolinski, B; Strandberg, T; Valiulis, A; Yorgancioglu, A; Zuberbier, T
  • No Thumbnail Available
    Item
    Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study
    Sousa-Pinto, B; Louis, R; Anto, JM; Amaral, R; Sá-Sousa, A; Czarlewski, W; Brussino, L; Canonica, GW; Loureiro, CC; Cruz, AA; Gemicioglu, B; Haahtela, T; Kupczyk, M; Kvedariene, V; Larenas-Linnemann, DE; Okamoto, Y; Ollert, M; Pfaar, O; Pham-Thi, N; Puggioni, F; Regateiro, FS; Romantowski, J; Sastre, J; Scichilone, N; Taborda-Barata, L; Ventura, MT; Agache, I; Bedbrook, A; Becker, S; Bergmann, KC; Bosnic-Anticevich, S; Bonini, M; Boulet, LP; Brusselle, G; Buhl, R; Cecchi, L; Charpin, D; de Blay, F; Del Giacco, S; Ivancevich, JC; Jutel, M; Klimek, L; Kraxner, H; Kuna, P; Laune, D; Makela, M; Morais-Almeida, M; Nadif, R; Niedoszytko, M; Papadopoulos, NG; Papi, A; Patella, V; Pétré, B; Yeverino, DR; Cordeiro, CR; Roche, N; Rouadi, PW; Samolinski, B; Savouré, M; Shamji, MH; Sheikh, A; Ulrik, CS; Usmani, OS; Valiulis, A; Yorgancioglu, A; Zuberbier, T; Fonseca, JA; Costa, EM; Bousquet, J
    Introduction Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting beta 2-agonists (ICS+LABA) in users of the MASK-air((R)) app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA. Materials and methods We analysed complete weeks of MASK-air((R)) data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day. Results In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication =80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001). Conclusions In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.